Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candesartan and ETB Receptor Function in Obesity
NCT03583866Phase 1Active, not recruiting
- Sponsor
- Augusta University
- Start
- May 2018
- Primary completion
- Dec 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of candesartan in hypertension (HTN), sponsored by Augusta University. Primary endpoint: Flow-Mediated Dilation at 7 days. Started May 2018; status: active, not recruiting.
02
Drugs
candesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03583866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583866.